Securing Research and Development Funding Through Listing and Capital Increases
First written in FY2021. 9 of 24 entries say "Advanced", first in FY2023-Q3. Latest entry: 2026-10-19.
12 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In March 2026, we also introduced a share and stock acquisition rights issuance program to secure the capital needed for growth investments and the development of our business infrastructure. The program is positioned as a capital policy for securing funds in stages when necessary to pursue multiple growth initiatives in parallel, rather than merely to cover short-term funding needs.」
In March 2026, introduced a share and stock acquisition rights issuance program with CVI Investments, Inc. as the allottee to secure funds for growth investments and the development of the business infrastructure. - FY2025-H1Updated interim results for funds raised through the exercise of stock acquisition rightsAnnual report
「During the interim accounting period, stock acquisition rights related to bonds with stock acquisition rights subject to revised exercise-price provisions and similar instruments were exercised as follows.」 Number of shares delivered upon exercise during the interim accounting period: 2,750,600. 「Funds raised through exercises during the interim accounting period: ¥946.139 million.」
Reports interim results showing that 2,750,600 shares were delivered through the exercise of the fourth series of stock acquisition rights and ¥946.139 million was raised. - FY2024-Q2Updated second-quarter results for funds raised through the issuance of sharesAnnual report
「Funds obtained from financing activities during the cumulative second-quarter period amounted to ¥308.339 million, compared with an outflow of ¥79.946 million in the same period of the previous fiscal year. This mainly reflected proceeds of ¥388.258 million from the issuance of shares and ¥80.004 million in repayments of long-term borrowings.」
Updates the cumulative second-quarter results for funds raised, including ¥388.258 million in proceeds from the issuance of shares through the exercise of the fourth series of stock acquisition rights and other transactions. - FY2024-Q1Updated results for funds raised through the exercise of stock acquisition rightsAnnual report
「During the first quarter, stock acquisition rights related to bonds with stock acquisition rights subject to revised exercise-price provisions and similar instruments were exercised as follows.」 Number of shares delivered upon exercise during the first quarter: 822,500. 「Funds raised through exercises during the first quarter: ¥259.522 million.」
Updated results for the fourth series of stock acquisition rights, under which 822,500 shares were delivered and ¥259.522 million was raised in the first quarter. - FY2023-Q3AdvancedAnnual report
「The stock acquisition rights issued under the Companies Act during the first nine months of the fiscal year were as follows.」 The class, terms and number of shares underlying the stock acquisition rights (shares): Common shares, 5,300,000. 「From 1 January 2023 through 31 January 2023, the number of issued shares increased by 598,300 through the exercise of stock acquisition rights, while capital stock and capital reserves each increased by ¥100.744 million.」
Issued stock acquisition rights equivalent to 5,300,000 shares under the fourth series. During the period before filing, 598,300 shares, representing part of these rights, were exercised, increasing capital stock and capital reserves. - FY2022Updated annual results for funds raisedAnnual report
「Funds obtained from financing activities during the fiscal year amounted to ¥3,829.240 million, compared with an outflow of ¥332.402 million in the previous fiscal year. This mainly reflected proceeds of ¥3,616.623 million from the issuance of shares and a ¥372.625 million decrease in restricted deposits, partially offset by ¥160.008 million in repayments of long-term borrowings.」
Reports annual results for funds raised through the listing and capital increase, including ¥3,616.623 million in proceeds from the issuance of shares. - FY2022-Q2RestatedAnnual report
「In connection with the listing, the issuance of 7,391,400 new shares through a public offering (book-building offering) with 21 April 2021 as the payment date increased both capital stock and capital surplus by ¥1,564.020 million. In addition, the issuance of 1,108,600 new shares through a third-party allotment (third-party allotment in connection with an over-allotment offering) with 24 May 2021 as the payment date increased both capital stock and capital surplus by ¥234.579 million.」
Provides specific details of funds raised for research and development and other purposes through the public offering and third-party allotment accompanying the listing. - FY2022-Q1RestatedAnnual report
「The Company was listed on the Tokyo Stock Exchange Mothers market on 22 April 2021. In connection with the listing, the issuance of 7,391,400 new shares through a public offering (book-building offering) with 21 April 2021 as the payment date increased both capital stock and capital surplus by ¥1,564.020 million. In addition, the issuance of 1,108,600 new shares through a third-party allotment (third-party allotment in connection with an over-allotment offering) with 24 May 2021 as the payment date increased both capital stock and capital surplus by ¥234.579 million.」
Provides specific details of the listing and funds raised through the public offering and third-party allotment. - FY2021First statedAnnual report
「April 2021: Listed on the Mothers market of the Tokyo Stock Exchange. The company planned to allocate funds raised through the public offering and other transactions at the time of listing to domestic and overseas R&D for expanding the indications for Steboronin®, repayment of long-term borrowings, and personnel expenses and other costs required for business operations and development.」
The company positioned its listing and public offering and private placement as sources of funding for R&D, debt repayment, personnel expenses and other costs.